Major pharmaceutical companies of the anti-inflammatory enzyme Streptokinase and Streptodornase have reportedly reached an agreement with the NHIS in redemption negotiations. The recovery rate, which has been an issue, is said to be in the early 20% range. It is interpreted as the result of the two sides' concessions to each other. According to the industry, major pharmaceutical companies such as the NHIS, Hanmi Pharmaceutical, and SK Chemicals, which held negotiations for the return with a deadline of the 14th, succeeded in reaching an agreement on the last day. Hanmi Pharmaceutical and SK Chemicals are ranked first and second in sales in related markets and are currently leading clinical re-evaluations.